At-a-Glance

COVID-19 Vaccination Schedule for Most People
(People who are NOT Moderately or Severely Immunocompromised)

People ages 6 months through 4 years

- Pfizer-BioNTech
  - Primary
  - In 3-8 weeks
  - OR-
  - Primary
  - In at least 8 weeks

People ages 5 through 11 years

- Moderna
  - Primary
  - In 4-8 weeks
  - OR-
  - Primary
  - In 4-8 weeks (Novavax, Pfizer) or in 4-8 weeks (Moderna)

- Pfizer-BioNTech
  - Primary
  - In at least 2 months
  - Bivalent booster

People ages 12 years and older

- Moderna, Novavax, or Pfizer-BioNTech
  - Primary
  - In 3-8 weeks (Novavax, Pfizer)
  - or in 4-8 weeks (Moderna)
  - Primary
  - In at least 2 months
  - Bivalent booster

People ages 18 years and older who previously received Janssen primary series dose†

- Primary
  - In at least 2 months
  - Bivalent booster

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a

For more specific clinical guidance, see:
- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

People ages 6 months through 4 years

Modern

- Primary  In 4 weeks  Primary  -OR-  Pfizer-BioNTech

Primary  In at least 4 weeks  Primary

People ages 5 years through 11 years

Modern

- Primary  In 4 weeks  Primary  -OR-  Pfizer-BioNTech

Primary  In at least 4 weeks  Primary

For more specific clinical guidance, see:
- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
At-a-Glance

COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

People ages 12 years and older

**Moderna or Pfizer-BioNTech**

- Primary
- In 3-8 weeks (Pfizer) or in 4 weeks (Moderna)
- Primary
- In at least 4 weeks
- Primary
- In at least 2 months
- Bivalent booster*

**Novavax**

- Primary
- In 3 weeks
- Primary
- In at least 2 months
- Bivalent booster*

-OR-

**Primary**

- In at least 4 weeks
- Addl mRNA dose
- In at least 2 months
- Bivalent booster*

People ages 18 years and older who previously received Janssen primary series dose†

**Primary**

- In at least 4 weeks
- Addl mRNA dose
- In at least 2 months
- Bivalent booster*

Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

**People ages 12 years and older (must weigh at least 40kg)**

- Any dose (primary or booster)
- In at least 2 weeks
- **EVUSHELD™ dose every 6 months**
- No minimum interval from EVUSHELD™ to COVID-19 vaccine
- Any subsequent COVID-19 vaccine dose

- At least 2 weeks from COVID-19 vaccine to EVUSHELD™

For more specific clinical guidance, see:

- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

**Note:** This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: [https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)